Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.93
LIFE's Cash-to-Debt is ranked lower than
64% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. LIFE: 3.93 )
Ranked among companies with meaningful Cash-to-Debt only.
LIFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54  Med: 11.42 Max: 26.72
Current: 3.93
1.54
26.72
Debt-to-Equity 0.36
LIFE's Debt-to-Equity is ranked lower than
57% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. LIFE: 0.36 )
Ranked among companies with meaningful Debt-to-Equity only.
LIFE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.11  Med: 0.04 Max: 0.36
Current: 0.36
-0.11
0.36
Debt-to-EBITDA -0.29
LIFE's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. LIFE: -0.29 )
Ranked among companies with meaningful Debt-to-EBITDA only.
LIFE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.45  Med: -0.27 Max: -0.11
Current: -0.29
-0.45
-0.11
Interest Coverage N/A
LIFE's Interest Coverage is ranked lower than
64% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LIFE: N/A )
Ranked among companies with meaningful Interest Coverage only.
LIFE' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: N/A
Piotroski F-Score: 1
Altman Z-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -82.66
LIFE's ROE % is ranked lower than
70% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. LIFE: -82.66 )
Ranked among companies with meaningful ROE % only.
LIFE' s ROE % Range Over the Past 10 Years
Min: -399.23  Med: -232.15 Max: -65.06
Current: -82.66
-399.23
-65.06
ROA % -65.87
LIFE's ROA % is ranked lower than
73% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. LIFE: -65.87 )
Ranked among companies with meaningful ROA % only.
LIFE' s ROA % Range Over the Past 10 Years
Min: -80.59  Med: -59.44 Max: -50.3
Current: -65.87
-80.59
-50.3
ROC (Joel Greenblatt) % -3062.79
LIFE's ROC (Joel Greenblatt) % is ranked lower than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. LIFE: -3062.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LIFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3605.48  Med: -1812.39 Max: -780.12
Current: -3062.79
-3605.48
-780.12
» LIFE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

LIFE Guru Trades in Q3 2016

Jim Simons 69,200 sh (New)
» More
Q4 2016

LIFE Guru Trades in Q4 2016

Jim Simons 38,100 sh (-44.94%)
» More
Q1 2017

LIFE Guru Trades in Q1 2017

Jim Simons 38,800 sh (+1.84%)
» More
Q2 2017

LIFE Guru Trades in Q2 2017

Jim Simons 60,300 sh (+55.41%)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:XTAE:CBI, XCNQ:PBT.U, TPE:1734, NAS:AXSM, OSTO:SANION, ASX:PNV, XTER:MGN, XTER:VSC, TSX:RVX, NAS:PRQR, OTCPK:EGRN, NAS:SRNE, ROCO:4193, NAS:CDTX, XPAR:ADOC, NAS:FWP, AMEX:SYN, TSE:2385, OSL:BGBIO, NAS:CBMG » details
Traded in other countries:471.Germany,
Headquarter Location:USA
aTyr Pharma Inc is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology.

aTyr Pharma Inc is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Business activity is primarily conducted through the United States.

Top Ranked Articles about aTyr Pharma Inc

Andreas Halvorsen Dives into Deciphera Pharma Company launches initial public offering and reports recent study results
Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, invested in 2,479,867 shares of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) for $19.73 per share on Oct. 2, according to GuruFocus real-time picks. Read more...
aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
aTyr Pharma to Present at Two Upcoming Investor Conferences in September
aTyr Pharma Announces $45 Million Equity Financing
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
aTyr Pharma Announces First Quarter 2017 Operating Results
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy

Ratios

vs
industry
vs
history
PB Ratio 2.98
LIFE's PB Ratio is ranked higher than
63% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. LIFE: 2.98 )
Ranked among companies with meaningful PB Ratio only.
LIFE' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.9
Current: 2.98
0
3.9
EV-to-EBIT -2.05
LIFE's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. LIFE: -2.05 )
Ranked among companies with meaningful EV-to-EBIT only.
LIFE' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.97  Med: 0 Max: 0
Current: -2.05
-2.97
0
EV-to-EBITDA -2.09
LIFE's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. LIFE: -2.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
LIFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3  Med: 0 Max: 0
Current: -2.09
-3
0
Current Ratio 6.12
LIFE's Current Ratio is ranked higher than
64% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. LIFE: 6.12 )
Ranked among companies with meaningful Current Ratio only.
LIFE' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 6.88 Max: 12.69
Current: 6.12
1.63
12.69
Quick Ratio 6.12
LIFE's Quick Ratio is ranked higher than
66% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. LIFE: 6.12 )
Ranked among companies with meaningful Quick Ratio only.
LIFE' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 6.88 Max: 12.69
Current: 6.12
1.63
12.69

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.33
LIFE's Price-to-Net-Cash is ranked higher than
78% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. LIFE: 3.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LIFE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.94  Med: 1.78 Max: 4.9
Current: 3.33
0.94
4.9
Price-to-Net-Current-Asset-Value 3.16
LIFE's Price-to-Net-Current-Asset-Value is ranked higher than
80% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. LIFE: 3.16 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LIFE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.9  Med: 1.71 Max: 4.74
Current: 3.16
0.9
4.74
Price-to-Tangible-Book 2.98
LIFE's Price-to-Tangible-Book is ranked higher than
72% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. LIFE: 2.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LIFE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 1.64 Max: 3.14
Current: 2.98
0.76
3.14
Earnings Yield (Greenblatt) % -48.72
LIFE's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. LIFE: -48.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LIFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -674.59  Med: 0 Max: 13069.07
Current: -48.72
-674.59
13069.07

More Statistics

EPS (TTM) $ -2.18
Short Percentage of Float2.38%
52-Week Range $2.10 - 6.50
Shares Outstanding (Mil)29.71

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}